Press release
Marginal Zone Lymphoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2024
Marginal Zone Lymphoma Pipeline
Key Takeaways from the Marginal Zone Lymphoma Pipeline Report
• DelveInsight's Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
• The leading companies working in the Marginal Zone Lymphoma Market include Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others
• Promising Marginal Zone Lymphoma Pipeline Therapies in the various stages of development include Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673, LOXO-305, and others.
• December 2023: Nurix Therapeutics Inc. announced a study of Phase 1 clinical trials for NX-5948. This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
• December 2023: John Lister announced a study of Phase 2 clinical trials for Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous). This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
• December 2023: Fred Hutchinson Cancer Center announced a study of Phase 1 & 2 clinical trials for Cyclophosphamide and Leukapheresis. The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).
• December 2023: Beigene announced a study of Phase 1 & 2 clinical trials for BGB-10188, Zanubrutinib and Tislelizumab. The purpose of this study is to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell malignancies; in combination with zanubrutinib in participants with R/R follicular lymphoma (FL), R/R mantle cell lymphoma (MCL) or R/R diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors.
Request a sample and discover the recent advances in Marginal Zone Lymphoma Treatment Drugs @ Marginal Zone Lymphoma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Marginal Zone Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Marginal Zone Lymphoma NDA approvals (if any), and product development activities comprising the technology, Marginal Zone Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Marginal Zone Lymphoma Overview
Marginal zone lymphoma (MZL) is the second most common indolent non-Hodgkin's lymphoma (iNHL). There are three types of marginal zone lymphomas: the extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT or gastric GALT), the splenic MZL, and the nodal MZL. EMZL can originate at virtually any extranodal site and arises in organs that normally lack lymphoid tissue (eg, stomach, intestine, thyroid, lung, and skin).
Find out more about Marginal Zone Lymphoma Therapeutics Assessment @ Marginal Zone Lymphoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Marginal Zone Lymphoma Emerging Drugs Profile
• Tafasitamab: Incyte Corporation
• Amdizalisib (HMPL-689): HUTCHMED
• Orelabrutinib: InnoCare Pharma
• EO2463: Enterome
Marginal Zone Lymphoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies that are developing therapies for Marginal Zone Lymphoma. The Marginal Zone Lymphoma companies have their Marginal Zone Lymphoma drug.
DelveInsight's Marginal Zone Lymphoma pipeline report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Marginal Zone Lymphoma Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Learn more about the emerging Marginal Zone Lymphoma Pipeline Therapies @ Marginal Zone Lymphoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Marginal Zone Lymphoma Pipeline Report
• Coverage- Global
• Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Marginal Zone Lymphoma Companies- Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others
• Marginal Zone Lymphoma Pipeline Therapies- Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673, LOXO-305, and others.
Dive deep into rich insights for new drugs for Marginal Zone Lymphoma Treatment, Visit @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Marginal Zone Lymphoma Executive Summary
3. Marginal Zone Lymphoma Overview
4. Marginal Zone Lymphoma Pipeline Therapeutics
5. Marginal Zone Lymphoma Pipeline Therapeutic Assessment
6. Marginal Zone Lymphoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tafasitamab: Incyte Corporation
9. Mid Stage Products (Phase II)
10. Orelabrutinib: InnoCare Pharma
11. Early Stage Products (Phase I/II)
12. EO2463: Enterome
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Marginal Zone Lymphoma Key Companies
17. Marginal Zone Lymphoma Key Products
18. Marginal Zone Lymphoma- Unmet Needs
19. Marginal Zone Lymphoma- Market Drivers and Barriers
20. Marginal Zone Lymphoma- Future Perspectives and Conclusion
21. Marginal Zone Lymphoma Analyst Views
22. Marginal Zone Lymphoma Key Companies
23. Appendix
For further information on the Marginal Zone Lymphoma Pipeline therapeutics, reach out to Marginal Zone Lymphoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
https://www.delveinsight.com/report-store/glaucoma-market
https://www.delveinsight.com/report-store/uveitis-market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
https://www.delveinsight.com/report-store/short-bowel-syndrome-market
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
https://www.delveinsight.com/report-store/aplastic-anemia-market
https://www.delveinsight.com/report-store/cystic-fibrosis-market
https://www.delveinsight.com/report-store/heart-failure-market
https://www.delveinsight.com/report-store/peanut-allergy-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/post-operative-pain-management-market
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Marginal Zone Lymphoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2024 here
News-ID: 3403478 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Marginal
Marginal-lubricating Bearings Market to Witness Robust Expansion by 2025
The latest research report"Global Marginal-lubricating Bearings Market Growth 2025-2031" studied by LP Information offers a comprehensive overview of theMarginal-lubricating Bearings market, providing insights into its drivers, restraints, and future trends. This study employs both primary and secondary research methods to offer unbiased perspectives on the globalMarginal-lubricating Bearings industry, assisting decision-makers in making informed business choices.
The research employs Porter's Five Forces analysis and SWOT analysis to offer a clear understanding…
Marginal Zone Lymphoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Marginal Zone Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
Auto Injector Market In-Depth Analysis & Marginal Revenue Growth
An autoinjector (or auto-injector) is a medical device designed to deliver a dose of a particular drug. The injectors were initially designed to overcome the hesitation associated with self-administration of the needle-based drug delivery device.
Most autoinjectors are one-use, disposable, spring-loaded syringes. By design, autoinjectors are easy to use and are intended for self-administration by patients, or administration by untrained personnel. The site of injection depends on the drug loaded,…
Latest Trends in Marginal Zone Lymphoma Treatment Market 2020-2025
Market Overview
The Marginal Zone Lymphoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations during COVID-19 outbreak.
Market segmentation
Marginal Zone Lymphoma Treatment market is split by Type and Application. For…
A2P SMS Market Cost Profit and Marginal Revenue Analysis by 2026
In this Report Titled Global A2P SMS Market Growth (Status and Outlook) 2019-2026 the latest data has been delivered, along with collection of realistic information, quantitative and qualitative estimation by industry experts, and the contribution from industry associates across the value chain. This report is a vast research database spread across various pages with numerous tables, charts, and figures in it. This report presents a close watch on the dominating…
Baking Fats Market In-Depth Analysis & Marginal Revenue Growth 2020-2026
How will be investment trends and competition in the global Baking Fats market during forecast period 2020-2026? Get the detail insights from QY Research.
Los Angeles, United State, February 2020: The report is just the right resource that global and regional Baking Fats players and investors need to peep into the future of their business and plan out effective growth strategies. It is a compilation of intelligent and accurate research and…
